Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-06-06
2006-06-06
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S241100, C424S282100, C424S202100, C424S209100, C424S217100, C424S278100, C424S240100, C424S254100, C424S257100, C424S261100, C514S002600
Reexamination Certificate
active
07056521
ABSTRACT:
The present invention provides parenteral adjuvants comprising detoxified mutants of bacterial ADP-ribosylating toxins, particularly those from pertussis (PT), cholera (CT), and heat-labileE. coli(LT).
REFERENCES:
patent: 5182109 (1993-01-01), Tamura et al.
patent: 6818222 (2004-11-01), Barchfeld et al.
patent: 0 145 486 (1985-06-01), None
patent: 0396964 (1990-11-01), None
patent: 0462534 (1991-12-01), None
patent: WO 92/19265 (1992-11-01), None
patent: WO 93/13202 (1993-07-01), None
patent: WO 95/17211 (1993-07-01), None
patent: WO 95/09649 (1995-04-01), None
patent: WO 95/34323 (1995-12-01), None
patent: WO 96/06627 (1996-03-01), None
patent: WO 97/02348 (1997-01-01), None
patent: WO 99/58145 (1999-11-01), None
patent: WO 00/18434 (2000-04-01), None
Agren, et al., “Genetically Engineered Nontoxic Vaccine Adjuvant That Combines B Cell Targeting with Immunomodulation by Cholera Toxin A1 Subunit,”J. Immunol.158:3936-3946 (1997).
Akhiani, et al., “Effect of Cholera Toxin on Vaccine-Induced Immunity and Infection in Murine Schistosomiasis Mansoni,”Infection and Immunity61(11): 4919-4924 (1993).
Bowen, et al., “Cholera Toxin Acts as a Potent Adjuvant for the Induction of Cytotoxic T-Lymphocyte Responses With Non-Replicating Antigens,”Immunology81:338-342 (1994).
Burnette, et al., “Site-Specific Mutagenisis of the Catalytic Subunit of Cholera Toxin: Substituting Lysine for Arginine 7 Causes Loss of Activity,”Infection and Immunity59(11):4266-4270 (1991).
Clements, et al., “Adjuvent Activity ofEscherichia coliHeat Labile Enterotoxin and Effect on the Induction of Oral Tolerance in Mice to Unrelated Protein Antigens,”Vaccine6:269-277.
Di Tommaso, et al., “Induction of Antigen-Specific Antibodies in Vaginal Secretions by Using a Nontoxic Mutant of Heat-Labile Enterotoxin as a Mucosal Adjuvant,”Infection and Immunity64(3): 974-979 (1996).
Douce, et al., “Mutants ofEscherichia coliHeat Labile Toxin Lacking ADP-Ribosyltransferase Activity Act as Nontoxic, Mucosal Adjuvants,”Proc. Natl. Acad. Sci. USA92:1644-1648 (1995).
Douce, et al., “Intranasal Immunogenecity and Adjuvanticity of Site-Directed Mutant Derivatives of Cholera Toxin,”Infection and Immunity65(7): 2821-2828 (1997).
Elson, et al., “Cholera Toxin as a Mucosal Adjuvant,”Mucosal Vaccines4:59-72 (1996).
Elson, et al., “Cholera Toxin and its Subunits as Potential Oral Adjuvants,”Curr. Top. Microbiol. Immonol.146:29-33 (1989).
Elson, et al., “A Lavage Technique Allowing Repeated Measurement of IgA Antibody in Mouse Intestinal Secretions,”Journal of Immunological Methods67:101-108 (1984).
Elson, et al., “Generalized Systematic and Mucosal Immunity in Mice After Mucosal Stimulation with Cholera Toxin,”The Journal of Immunology132(6): 2736-2741 (1984).
Elson, et al., “Ir Gene Control of the Murine Secretory IgA Response to Cholera Toxin,”Eur. J. Immonol.17:425-428 (1987).
Elson, et al., “Cholera Toxin Feeding Did Not Induce Oral Tolerance in Mice and Abrogated Oral Tolerance to an Unrelated Protein Antigen,”The Journal of Immunology133(6): 2829-2897 (1984).
Fontana, et al., “Construction of Nontoxic Derivatives of Cholera Toxin and Characterization of the Immunological Response Against the A Subunit,”Infection and Immunity64(12): 5434-5438 (1996).
Gizurarson, et al., “The Effect of Cholera Toxin and Cholera Toxin B Subunit on the Nasal Mucosal Membrane,”Vaccine9:825-832 (1991).
Glenn, et al., “Skin Immunization Made Possible by Cholera Toxin,”NATURE391:851 (1998).
Harford, et al., “Inactivation of theEscherichia coliHeat-Labile Enterotoxin byIn VitroMutagenesis of the A-Subunit Gene,”Eur. J. Biochem.183:311-316 (1989).
Hirabayashi, et al., “Involvement of Antigen-Presenting Cells in the Enhancement of theIn VitroAntibody Responses by Cholera Toxin B Subunit,”Immunology75:493-498 (1992).
Hirabayashi, et al., “Comparison of Intranasal Inoculation of Influenza HA Vaccine Combined With Cholera Toxin B Subunit With Oral or Parenteral Vaccination,”Vaccine8:243-248 (1990).
Hirabayashi, et al., “H-2-Unrestricted Adjuvant Effect of Cholera Toxin B Subunit on Murine Antibody Responses to Influenza Virus Haemagglutinin,”Immunology72:329-335 (1991).
Holmgren, et al., “An Oral B Subunit: Whole Cell Vaccine Against Cholera,”Vaccine10(13): 911-914 (1992).
Holmgren, et al., “Cholera Toxin and Cholera B Subunit as Oral-Mucosal Adjuvant and Antigen Vector Systems,”Vaccine11:1179-1183 (1993).
Jackson, et al., “Optimizing Oral Vaccines: Induction of Systematic and Mucosal B-Cell and Antibody Responses to Tetanus Toxoid by Use of Cholera Toxin as an Adjuvant,”Infection and Immunity61(10): 4272-4279 (1993).
Kikuta, et al., “Cross-Protection Against Influenza B Type Virus Infection by Intranasal Inoculation of the HA Vaccines Combined with Cholera Toxin B Subunit,”Vaccine8:595-599 (1990).
Lycke, et al., “The Adjuvant Effect ofVibrio CholeraandEscherichia coliHeat Labile Enterotoxins is Linked to Their ADP- Ribosyltransferase Activity,”Eur. J. Immunol.22: 2277-2281 (1992).
Lyke, et al., “Strong Adjuvant Properties of Cholera Toxin on Gut Mucosal Immune Responses to Orally Presented Antigens,”Immunology59:301-308 (1986).
Magagnoli, et al., “Mutations in the A Subunit Affect Yield, Stability, and Protease Sensitivity on Nontoxic Derivatives of Heat-Labile Enterotoxin,”Infection and Immunity64(12): 5434-5438 (1996).
Nasher, et al., “Potent Immunologenicity of the B Subunits ofEscherichia coliHeat-Labile Enterotoxin: Receptor Binding is Essential and Induces Differential Modulation of Lymphocyte Subsets,”Proc. Natl. Acad. Sci. USA93:226-230 (1996).
Partidos, et al., “The Adjuvant Effect of a Non-Toxic Mutant of Heat-Labile Enterotoxin ofEscherichia colifor the Induction of Measles Virus-Specific CTL Responses After Intranasal Co-Immunization With a Synthetic Peptide,”Immunology89:483-487 (1996).
Pierce, “The Role of Antigen Form and Function in the Primary and Secondary Intestinal Immune Responses to Cholera Toxin and Toxoid in Rats,”J. Exp. Med.148:195-206 (1978).
Pierce, et al., “Cellular Kinetics of the Intestinal Immune Response to Cholera Toxoid in Rats,”J. Exp. Med.142:1550-1563 (1975).
Pizza, et al., “Probing the Structure-Activity Relationship ofEscherichia coliLT-A by Site-Directed Mutagenesis,”Molecular Micobiology14(1): 51-60 (1994).
Rollwagen, et al., “KilledCampylobacterElicits Immune Response and Protection When Administered with an Oral Adjuvant,”Vaccine11(13): 1316-1320 (1993).
Snider, “The Mucosal Adjuvant Activities of ADP-Ribosylating Bacterial Enterotoxins,”Critical Review in Immunology15(3&4): 317-348 (1995).
Tamura, et al., “Cross-Protection Against Influenza Virus Infection Afforded By a Trivalent Inactivated Vaccines Inoculated Intranasally with Cholera Toxin B Subunit,”The Journal of Immunology149(3): 981-988 (1992).
Tamura, et al., “Protection Against Influenza Virus Infection by a Two-Dose Regimen of Nasal Vaccination Using Vaccines Combined with Cholera Toxin B Subunit,”Vaccine7:314-320 (1989).
Tamura, et al., “Enhancement of Protective Antibody Responses by Cholera Toxin B Subunit Inoculated Intranasally With Influenza Vaccine,”Vaccine7:257-262 (1989).
Tamura, et al., “Protection Against Influenza Virus Infection by Vaccine Inoculated Intranasally With Cholera Toxin B Subunit,”Vaccine6:409-413 (1988).
Tamura, et al., “Effectiveness of Cholera Toxin B Subunit as an Adjuvant for Nasal Influenza Vaccination Despite Pre-Existing Immunity to CTB,”Vaccine7:503-505 (1989).
Tsuji, et al., “A Single Amino Acid Substitution in the A Subunit ofEscherichia coliEnterotoxin Results in
Barchfeld Gail
Del Giudice Giuseppe
Rappuoli Rino
Chiron Corporation
Devi S.
Hale Rebecca M.
Harbin Alisa A.
Pasternak Dahna S.
LandOfFree
Detoxified mutants of bacterial ADP-ribosylating toxins as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detoxified mutants of bacterial ADP-ribosylating toxins as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detoxified mutants of bacterial ADP-ribosylating toxins as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3684969